Compound-Specific Toxicities Detected in CFU-GM, Rat Kidney NRK Cells, Rat Bladder RBLAK Cells, and Rat Liver Slices following Batracylin or N-Acetyl Batracylin Exposure
Table 3
PCLS lysate marker content changes with treatment.
Group
Day
LDH
ALP
GGT
AST
ALT
Protein
HPC
BEC
BEC prolif.
Glycogen
U/L/mg protein
mg
% Viable
0–4
Vehicle control
1
35082 ± 4604
69 ± 12
8 ± 1
4424 ± 273
812 ± 79
1.1 ± 0.1
72 ± 3
90 ± 1
0.0 ± 0.0
0.1 ± 0.1
3
36448 ± 4924
116 ± 10
22 ± 3
4015 ± 425
562 ± 77
0.9 ± 0.1
71 ± 3
88 ± 1
0.0 ± 0.0
0.7 ± 0.1
7
30414 ± 4330
231 ± 45
153 ± 22
3710 ± 357
741 ± 149
0.7 ± 0.1
70 ± 3
93 ± 1
1.1 ± 0.2
1.9 ± 0.2
0.5 μM NAB
1
30446 ± 3961
60 ± 8
7 ± 2
4282 ± 491
636 ± 88
1.1 ± 0.2
72 ± 4
87 ± 2
0.0 ± 0.0
0.3 ± 0.1
3
32860 ± 4669
149 ± 28
18 ± 3
4486 ± 543
555 ± 84
0.9 ± 0.1
60 ± 3
85 ± 1
0.1 ± 0.1
0.8 ± 0.2
7
31278 ± 4467
210 ± 46
120 ± 18
3430 ± 324
818 ± 216
0.7 ± 0.1
63 ± 3
91 ± 1
1.5 ± 0.1
1.8 ± 0.3
2.5 μM NAB
1
31720 ± 5388
82 ± 16
7 ± 1
4142 ± 329
672 ± 77
1.2 ± 0.1
66 ± 5
84 ± 4
0.0 ± 0.0
0.2 ± 0.1
3
31740 ± 5243
128 ± 24
18 ± 3
4867 ± 663
532 ± 79
0.8 ± 0.1
51 ± 5
80 ± 4
0.0 ± 0.0
0.3 ± 0.1
7
27996 ± 4083
155 ± 28
83 ± 15
4031 ± 555
607 ± 154
0.7 ± 0.1
62 ± 4
90 ± 1
1.8 ± 0.3
1.7 ± 0.2
5 μM BAT
1
34629 ± 4768
66 ± 9
9 ± 1
4167 ± 255
777 ± 63
1.1 ± 0.1
77 ± 3
90 ± 0
0.0 ± 0.0
0.1 ± 0.1
3
35693 ± 6354
103 ± 17
22 ± 5
4507 ± 534
574 ± 127
0.8 ± 0.1
59 ± 4
85 ± 2
0.2 ± 0.1
0.4 ± 0.2
7
26113 ± 3956
148 ± 28
94 ± 18
4130 ± 576
601 ± 149
0.6 ± 0.1
60 ± 4
86 ± 3
1.4 ± 0.2
1.4 ± 0.2
25 μM BAT
1
33832 ± 4577
55 ± 11
6 ± 1
3920 ± 304
948 ± 283
1.3 ± 0.2
70 ± 4
87 ± 1
0.0 ± 0.0
0.0 ± 0.0
3
31164 ± 5851
68 ± 10
18 ± 3
5664 ± 550
461 ± 53
0.6 ± 0.1
51 ± 4
83 ± 2
0.1 ± 0.1
0.0 ± 0.0
7
22341 ± 3608
94 ± 12
110 ± 21
6919 ± 1022
370 ± 47
0.4 ± 0.0
41 ± 4
88 ± 1
1.4 ± 0.3
0.0 ± 0.0
Bold fields indicate one or more experiments demonstrated a significant difference from vehicle control. BEC proliferation and glycogen content were assigned scores (0–4) by a pathologist and averages were not assessed statistically.
